Quanterix’ Simoa Technology Advances the Field Toward a Sports-Related Concussion Blood Test
“Despite the considerable progress we’ve made in understanding the impact concussions can have on the brain, they remain a major health risk for athletes at all levels,” said
According to the
Conducted as part of the
Results of the study demonstrate a strong correlation between concussions and elevated GFAP, UCH-L1 and tau levels in the blood. This supports prevailing theories that a clinically viable concussion test will necessitate a panel of markers rather than relying on a single indicator. The research also broadens the understanding of mTBIs, which are often missed due to the subtlety of symptoms, supporting the use of GFAP and UCH-L1 as sensitive, acute markers for milder head trauma. While Nf-L interaction was not considered significant as a concussion indicator, findings support its use as a measure for seriousness of injury and triggered neuronal damage. Nf-L was the only marker elevated days after RTP in more severely injured athletes with loss of consciousness (LOC) or post-traumatic amnesia (PTA).
The study joins a catalogue of more than 600 peer-reviewed studies powered by Simoa. A considerable portion of this research focuses on how TBIs manifest and progress in high-risk groups, including military personnel, professional hockey players, Olympic boxers, professional football players and more.
“Since the earliest days of PPH and
To learn more about Quanterix’ neurology offerings, click here.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the
Staci Didner, (407) 734-7325
Investor Relations Contact: